Compare CRVS & LDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRVS | LDP |
|---|---|---|
| Founded | 2014 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 634.0M | 628.4M |
| IPO Year | 2016 | N/A |
| Metric | CRVS | LDP |
|---|---|---|
| Price | $8.38 | $21.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $13.75 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 102.5K |
| Earning Date | 11-04-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.91% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.54 | $16.16 |
| 52 Week High | $9.60 | $20.30 |
| Indicator | CRVS | LDP |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 45.20 |
| Support Level | $8.31 | $21.26 |
| Resistance Level | $9.60 | $21.44 |
| Average True Range (ATR) | 0.54 | 0.18 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 23.25 | 50.00 |
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
Cohen & Steers Ltd Duration Preferred & Income Fund, Inc. is a diversified, closed-end management investment company. Its primary investment objective is high current income and capital appreciation is its secondary investment objective. The Fund invests at least its managed assets in preferred and other income securities issued by U.S. and non-U.S. companies under normal market conditions.